PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS

Phase 1 Completed 16 enrolled University of Colorado, Denver

Non-randomizedSequentialOpen-labelTreatment

Summary

Study Objective: The objective of this Phase 1 open-label study is to establish the safety and tolerability of Corlicyte mesenchymal stem cells (MSCs) in the treatment of patients with chronic diabetic foot ulcers (DFUs).

Timeline

Start: 2019-11-12
Primary completion: 2023-08-01
Completion: 2023-08-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Corlicyte	Cell therapy	—	—

PHASE 1, OPEN-LABEL SAFETY STUDY OF UMBILICAL CORD LINING MESENCHYMAL STEM CELLS (CORLICYTE®) TO HEAL CHRONIC DIABETIC FOOT ULCERS

Summary

Timeline

Drugs

Indications